Adimab enters new antibody discovery programs

Therapeutic antibody developer Adimab says that it has initiated two new independent research collaborations. The first is with fellow USA-based Gilead Sciences (Nasdaq: GILD), which aims to identify therapeutic antibodies against two targets selected by Gilead.

In addition, Adimab has expanded one of its current partnerships to initiate a new project in the area of bispecific antibodies. Adimab also announced the achievement of several technical milestones from its ongoing collaborations with Novartis, Merck, Merrimack, and Genentech.

With more than 28 antibody discovery projects in the last three years, Adimab has become the industry’s most sought after partner for the development of therapeutic human antibodies. Adimab has enabled its partners, including Biogen Idec, Eli Lilly, Genentech, Gilead, Human Genome Sciences, Merck, Novartis, Novo Nordisk, Pfizer, and Roche to expand their biologics pipelines through a range of technology access arrangements, the company stated. Less than three years after Adimab launched its platform several antibodies discovered by the company have entered human clinical trials providing further evidence for the quality and speed of the platform.